News

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...
By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...
Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...
In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...
Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...
Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...